Amgen Inc ((AMGN)), AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. and AstraZeneca have initiated a Phase 3 clinical study titled ‘A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312).’ This study aims to evaluate the efficacy of adding tarlatamab to the existing treatment regimen of durvalumab, carboplatin, and etoposide in improving overall survival for patients with extensive stage small-cell lung cancer (ES-SCLC).
The study tests the experimental combination of tarlatamab, durvalumab, carboplatin, and etoposide against the active comparator of durvalumab, carboplatin, and etoposide. Tarlatamab, a drug administered intravenously, is the key intervention being assessed for its potential to enhance treatment outcomes.
This interventional study follows a randomized, parallel assignment model without masking, primarily focusing on treatment. Participants will receive the assigned drug combinations over four cycles, with the primary goal of determining the impact on overall survival.
The study is currently in the recruiting phase, with an estimated start date of August 29, 2025. The study was first submitted on May 27, 2025, and the latest update was submitted on August 13, 2025. These dates are crucial for tracking the study’s progress and anticipating future developments.
The outcome of this study could significantly influence the stock performance of Amgen and AstraZeneca, as successful results may enhance their market positions in the oncology sector. Investors should monitor this study closely, as positive findings could lead to increased investor confidence and potential market share gains over competitors.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.